{"data":[{"accessionNo":"0000919574-26-005637","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001590750","issuerName":"Viridian Therapeutics, Inc.","ticker":"VRDN","cusip":"92790C104","securityClass":"Common Stock, par value $0.01 per share","eventDate":"2026-08-19","reportingPerson":"Point72 Asset Management, L.P.","reportingCik":null,"personType":"PN","sharesOwned":5687507,"percentOfClass":5,"filedAt":"2026-08-20","canonicalUrl":"https://xoomar.com/markets/stocks/vrdn"},{"accessionNo":"0000919574-26-005637","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001590750","issuerName":"Viridian Therapeutics, Inc.","ticker":"VRDN","cusip":"92790C104","securityClass":"Common Stock, par value $0.01 per share","eventDate":"2026-08-19","reportingPerson":"Point72 Capital Advisors, Inc.","reportingCik":null,"personType":"CO","sharesOwned":5687507,"percentOfClass":5,"filedAt":"2026-08-20","canonicalUrl":"https://xoomar.com/markets/stocks/vrdn"},{"accessionNo":"0000919574-26-005637","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001590750","issuerName":"Viridian Therapeutics, Inc.","ticker":"VRDN","cusip":"92790C104","securityClass":"Common Stock, par value $0.01 per share","eventDate":"2026-08-19","reportingPerson":"Steven A. Cohen","reportingCik":null,"personType":"IN","sharesOwned":5687507,"percentOfClass":5,"filedAt":"2026-08-20","canonicalUrl":"https://xoomar.com/markets/stocks/vrdn"},{"accessionNo":"0001104659-26-097208","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001590750","issuerName":"Viridian Therapeutics, Inc.","ticker":"VRDN","cusip":"92790C104","securityClass":"Common Stock, $0.01 par value per share","eventDate":"2026-06-30","reportingPerson":"Senai Asefaw, M.D.","reportingCik":null,"personType":"IN","sharesOwned":6723788,"percentOfClass":6.1,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/vrdn"},{"accessionNo":"0001104659-26-097208","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001590750","issuerName":"Viridian Therapeutics, Inc.","ticker":"VRDN","cusip":"92790C104","securityClass":"Common Stock, $0.01 par value per share","eventDate":"2026-06-30","reportingPerson":"Paradigm BioCapital Advisors GP LLC","reportingCik":null,"personType":"OO","sharesOwned":6723788,"percentOfClass":6.1,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/vrdn"},{"accessionNo":"0001104659-26-097208","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001590750","issuerName":"Viridian Therapeutics, Inc.","ticker":"VRDN","cusip":"92790C104","securityClass":"Common Stock, $0.01 par value per share","eventDate":"2026-06-30","reportingPerson":"Paradigm BioCapital Advisors LP","reportingCik":null,"personType":"PN","sharesOwned":6723788,"percentOfClass":6.1,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/vrdn"},{"accessionNo":"0001907884-26-000016","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001590750","issuerName":"Viridian Therapeutics, Inc.","ticker":"VRDN","cusip":"92790C104","securityClass":"Common Stock, $0.01 par value","eventDate":"2026-06-30","reportingPerson":"Kynam Capital Management, LP","reportingCik":null,"personType":"IA","sharesOwned":0,"percentOfClass":5.7,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/vrdn"},{"accessionNo":"0001907884-26-000016","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001590750","issuerName":"Viridian Therapeutics, Inc.","ticker":"VRDN","cusip":"92790C104","securityClass":"Common Stock, $0.01 par value","eventDate":"2026-06-30","reportingPerson":"Kynam Capital Management GP, LLC","reportingCik":null,"personType":"OO","sharesOwned":0,"percentOfClass":5.7,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/vrdn"},{"accessionNo":"0001907884-26-000016","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001590750","issuerName":"Viridian Therapeutics, Inc.","ticker":"VRDN","cusip":"92790C104","securityClass":"Common Stock, $0.01 par value","eventDate":"2026-06-30","reportingPerson":"Yue Tang","reportingCik":null,"personType":"IN","sharesOwned":0,"percentOfClass":5.7,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/vrdn"},{"accessionNo":"0001104659-26-097208","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001590750","issuerName":"Viridian Therapeutics, Inc.","ticker":"VRDN","cusip":"92790C104","securityClass":"Common Stock, $0.01 par value per share","eventDate":"2026-06-30","reportingPerson":"Paradigm BioCapital International Fund Ltd.","reportingCik":null,"personType":"CO","sharesOwned":5896154,"percentOfClass":5.3,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/vrdn"},{"accessionNo":"0000080255-26-000556","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001590750","issuerName":"VIRIDIAN THERAPEUTICS INC","ticker":"VRDN","cusip":"92790C104","securityClass":"COMMON STOCK","eventDate":"2026-06-30","reportingPerson":"T. Rowe Price Associates, Inc.","reportingCik":null,"personType":"IA","sharesOwned":5748426,"percentOfClass":5.2,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/vrdn"},{"accessionNo":"0001172661-26-003486","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001590750","issuerName":"VIRIDIAN THERAPEUTICS, INC.","ticker":"VRDN","cusip":"92790C104","securityClass":"Common Stock, $0.01 par value","eventDate":"2026-06-30","reportingPerson":"Deep Track Biotechnology Master Fund, Ltd.","reportingCik":null,"personType":"CO","sharesOwned":3592740,"percentOfClass":3.25,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/vrdn"},{"accessionNo":"0001172661-26-003486","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001590750","issuerName":"VIRIDIAN THERAPEUTICS, INC.","ticker":"VRDN","cusip":"92790C104","securityClass":"Common Stock, $0.01 par value","eventDate":"2026-06-30","reportingPerson":"Deep Track Capital, LP","reportingCik":null,"personType":"IA,OO","sharesOwned":3592740,"percentOfClass":3.25,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/vrdn"},{"accessionNo":"0001172661-26-003486","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001590750","issuerName":"VIRIDIAN THERAPEUTICS, INC.","ticker":"VRDN","cusip":"92790C104","securityClass":"Common Stock, $0.01 par value","eventDate":"2026-06-30","reportingPerson":"David Kroin","reportingCik":null,"personType":"HC,IN","sharesOwned":3592740,"percentOfClass":3.25,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/vrdn"},{"accessionNo":"0000093751-26-000558","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001590750","issuerName":"VIRIDIAN THERAPEUTICS INC","ticker":"VRDN","cusip":"92790C104","securityClass":"COMMON STOCK","eventDate":"2026-06-30","reportingPerson":"STATE STREET CORPORATION","reportingCik":null,"personType":"HC","sharesOwned":6124976,"percentOfClass":5.5,"filedAt":"2026-08-07","canonicalUrl":"https://xoomar.com/markets/stocks/vrdn"},{"accessionNo":"0001104659-26-078245","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001590750","issuerName":"Viridian Therapeutics, Inc.","ticker":"VRDN","cusip":"92790C104","securityClass":"Common Stock, $0.01 par value per share","eventDate":"2026-06-18","reportingPerson":"Senai Asefaw, M.D.","reportingCik":null,"personType":"IN","sharesOwned":5633788,"percentOfClass":5.1,"filedAt":"2026-06-26","canonicalUrl":"https://xoomar.com/markets/stocks/vrdn"},{"accessionNo":"0001104659-26-078245","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001590750","issuerName":"Viridian Therapeutics, Inc.","ticker":"VRDN","cusip":"92790C104","securityClass":"Common Stock, $0.01 par value per share","eventDate":"2026-06-18","reportingPerson":"Paradigm BioCapital Advisors GP LLC","reportingCik":null,"personType":"OO","sharesOwned":5633788,"percentOfClass":5.1,"filedAt":"2026-06-26","canonicalUrl":"https://xoomar.com/markets/stocks/vrdn"},{"accessionNo":"0001104659-26-078245","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001590750","issuerName":"Viridian Therapeutics, Inc.","ticker":"VRDN","cusip":"92790C104","securityClass":"Common Stock, $0.01 par value per share","eventDate":"2026-06-18","reportingPerson":"Paradigm BioCapital Advisors LP","reportingCik":null,"personType":"PN","sharesOwned":5633788,"percentOfClass":5.1,"filedAt":"2026-06-26","canonicalUrl":"https://xoomar.com/markets/stocks/vrdn"},{"accessionNo":"0001104659-26-078245","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001590750","issuerName":"Viridian Therapeutics, Inc.","ticker":"VRDN","cusip":"92790C104","securityClass":"Common Stock, $0.01 par value per share","eventDate":"2026-06-18","reportingPerson":"Paradigm BioCapital International Fund Ltd.","reportingCik":null,"personType":"CO","sharesOwned":4942532,"percentOfClass":4.5,"filedAt":"2026-06-26","canonicalUrl":"https://xoomar.com/markets/stocks/vrdn"},{"accessionNo":"0001104659-26-062332","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001590750","issuerName":"Viridian Therapeutics, Inc.","ticker":"VRDN","cusip":"92790C104","securityClass":"Common Stock","eventDate":"2026-03-31","reportingPerson":"Bellevue Asset Management AG","reportingCik":null,"personType":"CO","sharesOwned":6726144,"percentOfClass":6.6,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/vrdn"},{"accessionNo":"0001104659-26-062332","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001590750","issuerName":"Viridian Therapeutics, Inc.","ticker":"VRDN","cusip":"92790C104","securityClass":"Common Stock","eventDate":"2026-03-31","reportingPerson":"Bellevue Group AG","reportingCik":null,"personType":"HC,CO","sharesOwned":6726144,"percentOfClass":6.6,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/vrdn"},{"accessionNo":"0001104659-26-060292","formType":"SCHEDULE 13D/A","amendmentNo":8,"issuerCik":"0001590750","issuerName":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","cusip":"92790C104","securityClass":"Common Stock, $0.01 par value per share","eventDate":"2026-05-11","reportingPerson":"Fairmount Healthcare Fund II GP LLC","reportingCik":"0001830382","personType":"PN","sharesOwned":17201800,"percentOfClass":14.04,"filedAt":"2026-05-13","canonicalUrl":"https://xoomar.com/markets/stocks/vrdn"},{"accessionNo":"0001104659-26-060292","formType":"SCHEDULE 13D/A","amendmentNo":8,"issuerCik":"0001590750","issuerName":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","cusip":"92790C104","securityClass":"Common Stock, $0.01 par value per share","eventDate":"2026-05-11","reportingPerson":"Fairmount Funds Management LLC","reportingCik":"0001802528","personType":"IA","sharesOwned":17201800,"percentOfClass":14.04,"filedAt":"2026-05-13","canonicalUrl":"https://xoomar.com/markets/stocks/vrdn"},{"accessionNo":"0001172661-26-001638","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001590750","issuerName":"VIRIDIAN THERAPEUTICS, INC.","ticker":"VRDN","cusip":"92790C104","securityClass":"Common Stock, $0.01 par value per share","eventDate":"2026-05-01","reportingPerson":"Deep Track Biotechnology Master Fund, Ltd.","reportingCik":null,"personType":"CO","sharesOwned":5417660,"percentOfClass":5.3,"filedAt":"2026-05-08","canonicalUrl":"https://xoomar.com/markets/stocks/vrdn"},{"accessionNo":"0001172661-26-001638","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001590750","issuerName":"VIRIDIAN THERAPEUTICS, INC.","ticker":"VRDN","cusip":"92790C104","securityClass":"Common Stock, $0.01 par value per share","eventDate":"2026-05-01","reportingPerson":"David Kroin","reportingCik":null,"personType":"HC,IN","sharesOwned":5417660,"percentOfClass":5.3,"filedAt":"2026-05-08","canonicalUrl":"https://xoomar.com/markets/stocks/vrdn"},{"accessionNo":"0001172661-26-001638","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001590750","issuerName":"VIRIDIAN THERAPEUTICS, INC.","ticker":"VRDN","cusip":"92790C104","securityClass":"Common Stock, $0.01 par value per share","eventDate":"2026-05-01","reportingPerson":"Deep Track Capital, LP","reportingCik":null,"personType":"IA,OO","sharesOwned":5417660,"percentOfClass":5.3,"filedAt":"2026-05-08","canonicalUrl":"https://xoomar.com/markets/stocks/vrdn"},{"accessionNo":"0000102909-26-002586","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001590750","issuerName":"Viridian Therapeutics Inc","ticker":"VRDN","cusip":"92790C104","securityClass":"Common Stock","eventDate":"2026-03-13","reportingPerson":"The Vanguard Group","reportingCik":null,"personType":"IA","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-03-27","canonicalUrl":"https://xoomar.com/markets/stocks/vrdn"},{"accessionNo":"0001907884-26-000004","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001590750","issuerName":"Viridian Therapeutics, Inc.","ticker":"VRDN","cusip":null,"securityClass":"Common Stock, $0.01 par value","eventDate":"2025-12-31","reportingPerson":"Kynam Capital Management, LP","reportingCik":null,"personType":"IA","sharesOwned":1470541,"percentOfClass":1.54,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/vrdn"},{"accessionNo":"0001907884-26-000004","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001590750","issuerName":"Viridian Therapeutics, Inc.","ticker":"VRDN","cusip":null,"securityClass":"Common Stock, $0.01 par value","eventDate":"2025-12-31","reportingPerson":"Kynam Capital Management GP, LLC","reportingCik":null,"personType":"OO","sharesOwned":1470541,"percentOfClass":1.54,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/vrdn"},{"accessionNo":"0001907884-26-000004","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001590750","issuerName":"Viridian Therapeutics, Inc.","ticker":"VRDN","cusip":null,"securityClass":"Common Stock, $0.01 par value","eventDate":"2025-12-31","reportingPerson":"Yue Tang","reportingCik":null,"personType":"IN","sharesOwned":1470541,"percentOfClass":1.54,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/vrdn"},{"accessionNo":"0001172661-26-000723","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001590750","issuerName":"Viridian Therapeutics, Inc.","ticker":"VRDN","cusip":null,"securityClass":"Common Stock, $0.01 par value per share","eventDate":"2025-12-31","reportingPerson":"Deep Track Biotechnology Master Fund, Ltd.","reportingCik":null,"personType":"CO","sharesOwned":2524833,"percentOfClass":2.65,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/vrdn"},{"accessionNo":"0001172661-26-000723","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001590750","issuerName":"Viridian Therapeutics, Inc.","ticker":"VRDN","cusip":null,"securityClass":"Common Stock, $0.01 par value per share","eventDate":"2025-12-31","reportingPerson":"Deep Track Capital, LP","reportingCik":null,"personType":"IA,OO","sharesOwned":2524833,"percentOfClass":2.65,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/vrdn"},{"accessionNo":"0001172661-26-000723","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001590750","issuerName":"Viridian Therapeutics, Inc.","ticker":"VRDN","cusip":null,"securityClass":"Common Stock, $0.01 par value per share","eventDate":"2025-12-31","reportingPerson":"David Kroin","reportingCik":null,"personType":"HC,IN","sharesOwned":2524833,"percentOfClass":2.65,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/vrdn"},{"accessionNo":"0001831942-25-000032","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001590750","issuerName":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","cusip":null,"securityClass":"Common Stock, $0.01 par value","eventDate":"2025-09-30","reportingPerson":"Commodore Capital LP","reportingCik":null,"personType":"IA,PN","sharesOwned":3200000,"percentOfClass":3.9,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/vrdn"},{"accessionNo":"0001831942-25-000032","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001590750","issuerName":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","cusip":null,"securityClass":"Common Stock, $0.01 par value","eventDate":"2025-09-30","reportingPerson":"Commodore Capital Master LP","reportingCik":null,"personType":"PN","sharesOwned":3200000,"percentOfClass":3.9,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/vrdn"},{"accessionNo":"0001104659-25-102608","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001590750","issuerName":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","cusip":null,"securityClass":"Common Stock, $0.01 par value","eventDate":"2025-10-23","reportingPerson":"Fairmount Funds Management LLC","reportingCik":"0001802528","personType":"IA","sharesOwned":16025330,"percentOfClass":15.14,"filedAt":"2025-10-27","canonicalUrl":"https://xoomar.com/markets/stocks/vrdn"},{"accessionNo":"0001104659-25-102608","formType":"SCHEDULE 13D/A","amendmentNo":7,"issuerCik":"0001590750","issuerName":"Viridian Therapeutics, Inc.\\DE","ticker":"VRDN","cusip":null,"securityClass":"Common Stock, $0.01 par value","eventDate":"2025-10-23","reportingPerson":"Fairmount Healthcare Fund II GP LLC","reportingCik":"0001830382","personType":"PN","sharesOwned":16025330,"percentOfClass":15.14,"filedAt":"2025-10-27","canonicalUrl":"https://xoomar.com/markets/stocks/vrdn"}],"updatedAt":"2026-11-05T13:27:47.296Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/vrdn","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}